Enhanced oral bioavailability of levormeloxifene and raloxifene by nanoemulsion: simultaneous bioanalysis using liquid chromatography-tandem mass spectrometry
- 19 April 2024
- journal article
- research article
- Published by Taylor & Francis in Nanomedicine
- Vol. 19 (12) , 1051-1068
Abstract
Aim & objective: Levormeloxifene (L-ORM) and raloxifene (RAL) are selective estrogen receptor modulators used in the treatment of postmenopausal osteoporosis and breast cancer. Here, we developed a... Graphical abstractKeywords
This publication has 48 references indexed in Scilit:
- Ratiometric codelivery of Paclitaxel and Baicalein loaded nanoemulsion for enhancement of breast cancer treatmentInternational Journal of Pharmaceutics, 2023
- Simultaneous assessment of ciprofloxacin and dexamethasone in ocular tear fluid by LC-MS/MS: Application to a pharmacokinetic study in rabbitsChinese Journal of Analytical Chemistry, 2022
- LC–MS/MS Method for Determination of Non-opioid Analgesics Adulterants in Herbal MedicinesChemistry Africa, 2022
- Raloxifene as a treatment option for viral infectionsJournal of Microbiology, 2021
- Development and validation of ultra‐high‐performance liquid chromatography–mass spectrometry method for the determination of raloxifene and its phase II metabolites in plasma: Application to pharmacokinetic studies in ratsJournal of Separation Science, 2020
- Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis?Osteoporosis International, 2020
- Estrogen therapy for osteoporosis in the modern eraOsteoporosis International, 2018
- Formulation, characterization and antimicrobial properties of black cumin essential oil nanoemulsions stabilized by OSA starchJournal of Food Science and Technology, 2017
- Therapeutic effect of centchroman alone and in combination with glycine soya on 7,12-dimethylbenz[α]anthracene-induced breast tumor in ratFood and Chemical Toxicology, 2010
- Update of current therapeutic options for the treatment of postmenopausal osteoporosisClinical Therapeutics, 2006